$12.2 Billion Worldwide Hemophilia Gene Therapy Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hemophilia Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Hemophilia Gene Therapy estimated at US$12.2 Billion in the year 2020, is projected to reach a revised size of US$15.8 Billion by 2027, growing at a CAGR of 3.8% over the analysis period 2020-2027.

Hemophilia A, one of the segments analyzed in the report, is projected to record a 3.6% CAGR and reach US$12.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hemophilia B segment is readjusted to a revised 4.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.6 Billion, While China is Forecast to Grow at 3.6% CAGR

The Hemophilia Gene Therapy market in the U.S. is estimated at US$3.6 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2027 trailing a CAGR of 3.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 3.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Other Segments Segment to Record 4% CAGR

In the global Other Segments segment, USA, Canada, Japan, China and Europe will drive the 4.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$186.7 Million in the year 2020 will reach a projected size of US$247 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.8 Billion by the year 2027.

Select Competitors (Total 44 Featured):

• Alnylam Pharmaceuticals, Inc.
• BioMarin Pharmaceutical, Inc.
• Shire PLC
• Spark Therapeutics, Inc.
• uniQure NV

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• Influencer Market Insights
• World Market Trajectories
• Impact of COVID-19 and a Looming Global Recession

III. MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 44

For more information about this report visit https://www.researchandmarkets.com/r/hptfrx

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900